Workshop on clinical trials of antibacterial agents for Hospital-acquired pneumonia and ventilator-associated pneumonia

Clinical Infectious Diseases

Volumn 51, Issue SUPPL. 1, 2010, Pages

  Bartlett, John G ^a   Barie, Philip S ^b   Niederman, Michael S ^c   Wunderink, Richard G ^d  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAZIDIME; CIPROFLOXACIN; LEVOFLOXACIN; LINEZOLID; LIPOPEPTIDE; OXAZOLIDINONE DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTIFICIAL VENTILATION; CLINICAL TRIAL; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG SCREENING; FOOD AND DRUG ADMINISTRATION; GRAM NEGATIVE BACTERIUM; HOSPITAL ACQUIRED PNEUMONIA; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MEDICAL SOCIETY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; PRIORITY JOURNAL; STUDY DESIGN; VENTILATOR ASSOCIATED PNEUMONIA; WORKSHOP; CLINICAL TRIAL (TOPIC); CROSS INFECTION; MICROBIOLOGY; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

ANTI-BACTERIAL AGENTS; CLINICAL TRIALS AS TOPIC; CROSS INFECTION; HUMANS; PNEUMONIA, BACTERIAL; PNEUMONIA, VENTILATOR-ASSOCIATED;

EID: 77955703963     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/653066     Document Type: Conference Paper

References (18)

1. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 49:992-993.
2. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-164.
3. European Centers for Disease Control and European Medicines Agency: technical report. The bacterial challenge: time to react. http://www.ecdc. europa.eu. Accessed 11 December, 2009.
4. Spellberg B, Talbot G; Infectious Diseases Society of America, American College of Chest Physicians, American Thoracic Society, Society of Critical Care Medicine. Recommended design features of future clinical trials of antibacterial agents for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 2010; 51(Suppl 1):S150-S170 (in this supplement).
5. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2006; 173:131-133.
6. Kieninger AN, Lipsett PA. Hospital-acquired pneumonia: pathophysiology, diagnosis, and treatment. Surg Clin North Am 2009;89: 439-461.
7. Rosenthal VD, Maki DG, Mehta A, et al.; International Nosocomial Infection Control Consortium Members. International Noso-comial Infection Control Consortium report, data summary for 2002-2007, issued January 2008. Am J Infect Control 2008; 36:627-637.
8. Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165:867-903.
9. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27:887-892.
10. Rello J, Sa-Borges M, Correa H, Leal SR, Bar-aibar J. Variations in etiology of ventilator-associated pneumonia across four treatment sites: implications for antimicrobial prescribing practices. Am J Respir Crit Care Med 1999; 160:608-613.
11. Canadian Critical Care Group. A randomized trial of diagnostic techniques for ventilator-associated pneumonia. N Engl J Med 2006; 355:2619-2630.
12. Kassowitz KE, Muscato GH Jr. The long range effect of antibacterial therapy on pneumonia, empyema, bronchiectasis and pulmonary abscess; an analysis of incidence and mortality in 74,489 admissions to a children's hospital in twenty years. Dis Chest 1952; 21:161-173.
13. Iregui M, Ward S, Sherman G, Fraser VJ, Kol-lef MH. Clinical importance of delays in the initiation of appropriate antibiotic treatment for ventilator-associated pneumonia. Chest 2002; 122:262-268.
14. Pertel PE, Bernardo P, Fogarty C, et al. Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 2008; 46:1152-1156.
15. Alvarez-Lerma F, Insausti-Ordenana J, Jorda-Marcos R, et al. Efficacy and tolerability of piperacillin/tazobactamversus ceftazidime in association with amikacin for treating noso-comial pneumonia in intensive care patients: a prospective randomized multicenter trial. Intensive Care Med 2001; 27:493-502.
16. Chastre J, Wunderink R, Prokocimer P, Lee M, Kaniga K, Friedland I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit Care Med 2008; 36:1089-1096.
17. Saravolatz LD, Stein GE, Johnson LB. Tela-vancin: a novel lipoglycopeptide. Clin Infect Dis 2009; 49(12):1908-1914.
18. Infectious Diseases Society of America. Grinding to a halt: the effects of the increasing regulatory burden on research and quality improvement efforts. Clin Infect Dis 2009; 49(3): 328-335.